Detalhe da pesquisa
1.
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Blood
; 138(21): 2138-2142, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499715
2.
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
Transplant Cell Ther
; 2024 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588880
3.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol
; 41(2): 354-363, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108252
4.
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Blood Adv
; 7(12): 2758-2771, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857419
5.
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Blood Adv
; 7(4): 541-548, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35938863
6.
Mediport use as an acceptable standard for CAR T cell infusion.
Front Immunol
; 14: 1239132, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965315
7.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
; 6(7): 1961-1968, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788386
8.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood Adv
; 6(2): 600-610, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794180
9.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
J Clin Oncol
; 40(9): 945-955, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882493
10.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Blood Adv
; 6(14): 4251-4255, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580324
11.
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
Best Pract Res Clin Haematol
; 34(3): 101305, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625231
12.
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses.
Blood Adv
; 5(2): 496-503, 2021 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33496746
13.
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.
J Clin Oncol
; 39(34): 3822-3828, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34591650
14.
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.
Bone Marrow Transplant
; 55(11): 2160-2169, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32390002
15.
Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force.
Transplant Cell Ther
; 28(10): 625-636, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870778